The Chemours Company

Second Quarter Earnings Presentation

August 3, 2018

Chemours™

Safe Harbor Statement and Other Matters

This presentation contains forward-looking statements, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," “will,” "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, anticipated future operating and financial performance, business plans and prospects, capital investments and projects, plans for dividends or share repurchases, sufficiency or longevity of intellectual property protection, cost savings targets, plans to increase profitability and growth, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, and our outlook for net sales, Adjusted EBITDA, Adjusted EPS, Free Cash Flow and Return on Invested Capital (ROIC), all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2017. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

We prepare our financial statements in accordance with Generally Accepted Accounting Principles (“GAAP”). Within this presentation we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Pre-tax Operating Income, Free Cash Flow, Return on Invested Capital (ROIC) and Net Leverage Ratio which are non-GAAP financial measures. The company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Further information with respect to and reconciliations of such measures to the nearest GAAP measure can be found in the appendix hereto.

Management uses Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Pre-tax Operating Income, Free Cash Flow, ROIC and Net Leverage Ratio to evaluate the company’s performance excluding the impact of certain noncash charges and other special items which we expect to be infrequent in occurrence in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Additional information for investors is available on the company’s website at investors.chemours.com.

Second Quarter 2018 Highlights

Delivered strong year-over-year increases across key financial metrics

Balanced performance across portfolio led by Ti-Pure™ titanium dioxide pigment and Opteon™ refrigerants

Completed $500M share repurchase plan and authorized new $750M plan through 2020

Increased dividend 47 percent to $0.25 per share from $0.17 per share

Reiterated 2018 full-year outlook; on track to meet or exceed three-year targets

Chemours™

Second Quarter 2018 Financial Summary

($ in millions unless otherwise noted)

	2Q18	2Q17	Δ Yr/Yr
Net Sales	$1,816	$1,588	*$228*
Net Income[1]	281	161	*120*
Adj. Net Income	314	164	*150*
EPS[2]	$1.53	$0.84	*$0.69*
Adj. EPS[2]	$1.71	$0.86	*$0.85*
Adj. EBITDA	497	361	*136*
Adj. EBITDA Margin (%) [3]	*27.4*	*22.7*	*4.7*
Free Cash Flow[4]	217	115	*102*
Pre-Tax ROIC (%)[5]	42	27	*15*

Year-Over-Year

- Broad-based revenue growth across segments drove 14% revenue increase
- Nearly doubled Adjusted EPS to $1.71 per share from $0.86 per share
- Adjusted EBITDA Margin expanded 470bps
- Significant Free Cash Flow improvement despite elevated capital expenditures
- Pre-tax ROIC of 42%, well above 30% threshold

[1] Net Income attributable to Chemours
[2] Calculation based on diluted share count
[3] Defined as Adjusted EBITDA divided by Net Sales
[4] Defined as Cash from Operations minus cash used for PP&E purchases
[5] Defined as Adjusted EBITDA less depreciation & amortization on a trailing twelve-month basis divided by average invested capital over the last five quarters

See reconciliation of Non-GAAP measures in the Appendix

Adjusted EBITDA Bridge: 2Q18 versus 2Q17

($ in millions unless otherwise noted)



Adjusted EPS Bridge: 2Q18 versus 2Q17

($ per share unless otherwise noted)



See reconciliation of Non-GAAP measures in the Appendix

[1] Based on average shares outstanding in 2Q18

Liquidity Position

($ in millions unless otherwise noted)



- June 30, 2018 ending cash balance of $1.2B
- Free Cash Flow of $217M[1] versus $115M in 2Q17
- Capital expenditures of $126M
- Raised €450M via senior unsecured notes
  - ~$16M[2] annual interest savings
  - Used to redeem existing Euro 2023 notes and portion of USD 2023 notes
- Total Liquidity of ~$2.0B, including revolver availability of $800M[3]
- Net debt of $2.8B, net leverage ratio[4] of ~1.6 times on a trailing twelve-month basis

[1] Includes cash restructuring payments of $13M in 2Q18
[2] Including credit facility, estimated annual interest savings total $28M
[3] Based on new revolving credit facility. Chemours had $105M in letters of credit outstanding as of June 30, 2018
[4] Senior Secured Net Debt/EBITDA is 0.3x based on Credit Agreement definition
[5] Reflects cash used for share repurchases and refinancing
* Includes Net Income attributable to non-controlling interests

See reconciliation of Non-GAAP measures in the Appendix

Returning Meaningful Cash to Shareholders

- Invest in organic growth
- Consider opportunistic M&A growth

- Meaningful return of cash to shareholders

- Maintain a BB/BB+ balance sheet

- Declared 3Q18 dividend of **$0.25 per share**
  - An **$0.08** increase per share
  - Expect **2018 annual dividend**[1] to be **~$150M**
  - Defensible through the cycle
  - Anticipate to grow with earnings
- Authorized **$750M** share repurchase plan through 2020
  - Completed previous $500M share repurchase plan during second quarter 2018
- Expect to return majority of generated Free Cash Flow to shareholders through 2020

1. Future dividend declarations subject to Board approval

Fluoroproducts Business Summary

Second Quarter Highlights

- Strong Opteon™ refrigerant growth primarily driven by stationary adoption in EU and mobile adoption in US and AP
- Base refrigerant revenue in line with previous year quarter, as higher price offset modestly lower volume
- Improved price for certain Fluoropolymers products; supply constraints impacting volume

2018 Outlook Commentary

- Sustained Opteon™ refrigerant momentum across auto and stationary applications
- Certain Fluoropolymers products expected to remain sold out; anticipating solid demand and higher price driven by previously announced price increases
- Planned major maintenance at Fluoropolymer facilities continuing in third quarter and process water treatment costs are headwinds in the year

Financial Summary *($ in millions)*

Net Sales



Sales Drivers

	Yr/Yr % Δ
Price	4
Currency	2
Volume	7

Adjusted EBITDA



See reconciliation of Non-GAAP measures in the Appendix

Chemical Solutions Business Summary

Second Quarter Highlights

- Modestly higher volume for Mining Solutions products
- Increased demand across most Performance Chemicals & Intermediates products
- Communicated price increases for certain product lines during the quarter

2018 Outlook Commentary

- Expect Mining Solutions and Glycolic Acid products to remain sold-out throughout year
- Anticipate favorable market conditions across Chemical Solutions businesses
- Construction of Mining Solutions facility in Laguna remains suspended

Financial Summary *($ in millions)*

Net Sales



Sales Drivers

	Yr/Yr % Δ
Price	(1)
Currency	1
Volume	3

Adjusted EBITDA



See reconciliation of Non-GAAP measures in the Appendix

Chemours™

Titanium Technologies Business Summary

Second Quarter Highlights

- Increased year-over-year price a result of previously communicated price increases
- Customers report reductions in TiO_2 inventory levels consistent with stabilizing prices, in line with Chemours expectations
- Higher raw material costs largely anticipated

2018 Outlook Commentary

- Expect volume for Ti-Pure™ pigment to be similar to previous year
- Managing production to meet our customers' anticipated demand; continue to focus on 10% debottlenecking opportunity through 2021
- Communicated price increase on August 1 to customers that are not on Ti-Pure™ Value Stabilization contracts

Financial Summary *($ in millions)*

Net Sales



Sales Drivers

	Yr/Yr % Δ
Price	16
Currency	3
Volume	(1)

Adjusted EBITDA



See reconciliation of Non-GAAP measures in the Appendix

2018 Outlook

Adjusted EBITDA

Top End Of:
$1.70 - $1.85 Billion

Adjusted EPS

$5.00 - $5.75

Free Cash Flow

> $700 Million

Key Factors and Assumptions[1]

- 2018 Ti-Pure™ realized average price above 2017 average price
- Continued Opteon™ adoption
- Fluoropolymers volume growth
- Includes benefit from ~$500M in completed share repurchases

See reconciliation of Non-GAAP measures in the Appendix

[1] Subject to risks, uncertainties and assumptions, all of which are described in our public filings and safe harbor statement

Expect to Meet or Exceed Three-Year Targets

2018 - 2020

REVENUE	1x – 2x GDP growth rate		
ADJUSTED EBITDA MARGINS	Improvement by ~500 basis points		
ADJUSTED EPS	15% – 20% CAGR		
ROIC	Maintain above 30%		
CUMULATIVE FCF	Generate $2 – $3 billion		
CASH RETURN TO SHAREHOLDERS	Dividend[1]	$0.17/share	$0.25/share
	Share repurchase	$500 million	$750 million

1. Subject to quarterly Board approval

Chemours Investment Thesis

Leveraging	industry-leading positions to drive top-line growth of 1x-2x GDP
Investing	in our core businesses with high ROIC (+30%) projects to drive sustainable competitive advantage
Strengthening	our existing businesses through targeted M&A
Returning	the majority of our Free Cash Flow to shareholders over time through a growing dividend and meaningful share repurchases
Harnessing	the energy of the organization, generated through the transformation, to move at high velocity

The Chemours Company

Appendix

Segment Net Sales and Adjusted EBITDA (Unaudited)

($ in millions unless otherwise noted)	Three Months Ended June 30, 2018	Three Months Ended June 30, 2017	Three Months Ended March 31, 2018
SEGMENT NET SALES			
Fluoroproducts	$ 801	$ 710	$ 732
Chemical Solutions	153	149	144
Titanium Technologies	862	729	854
Total Company	$ 1,816	$ 1,588	$ 1,730
SEGMENT ADJUSTED EBITDA			
Fluoroproducts	$ 230	$ 197	$ 206
Chemical Solutions	16	7	11
Titanium Technologies	295	193	294
Corporate & Other	(44)	(36)	(43)
Total Company	$ 497	$ 361	$ 468
SEGMENT ADJUSTED EBITDA MARGIN			
Fluoroproducts	28.7%	27.7%	28.1%
Chemical Solutions	10.5%	4.7%	7.6%
Titanium Technologies	34.2%	26.5%	34.4%
Corporate & Other	0.0%	0.0%	0.0%
Total Company	27.4%	22.7%	27.1%

GAAP Net Income Attributable to Chemours to Adjusted Net Income, Adjusted EBITDA, and Adjusted EPS Reconciliations (Unaudited)

($ in millions except per share amounts)	Three Months Ended June 30, 2018 $ amounts	Three Months Ended June 30, 2018 $ per share*	Three Months Ended June 30, 2017 $ amounts	Three Months Ended June 30, 2017 $ per share*	Three Months Ended March 31, 2018 $ amounts	Three Months Ended March 31, 2018 $ per share*
Net income attributable to Chemours	$ 281	$ 1.53	$ 161	$ 0.84	$ 297	$ 1.58
Non-operating pension and other post-retirement employee benefit income	(7)	(0.04)	(10)	(0.05)	(7)	(0.04)
Exchange gains, net	(2)	(0.01)	(2)	(0.01)	—	—
Restructuring and other charges	9	0.05	6	0.03	10	0.05
Asset-related and other charges	1	0.01	2	0.01	—	—
Loss on extinguishment of debt	38	0.21	1	0.01	—	—
(Gain) loss on sale of assets or businesses (1)	(3)	(0.02)	2	0.01	(42)	(0.22)
Transaction costs (2)	9	0.05	2	0.01	—	—
Legal and other charges (3)	10	0.05	10	0.05	4	0.02
Adjustments made to income taxes (4,6)	(8)	(0.04)	(3)	(0.02)	(5)	(0.03)
(Benefit from) provision for income taxes relating to reconciling items (5,6)	(14)	(0.08)	(5)	(0.03)	9	0.05
Adjusted Net Income	$ 314	$ 1.71	$ 164	$ 0.86	$ 266	$ 1.41
Net income attributable to non-controlling interests	1		—		—	
Interest expense, net	48		54		52	
All remaining depreciation and amortization	71		71		70	
All remaining provision for income taxes (6)	63		72		80	
Adjusted EBITDA	$ 497		$ 361		$ 468	
Weighted-average number of common shares outstanding - basic	177,798,484		185,069,436		182,069,982	
Weighted-average number of common shares outstanding - diluted	183,821,241		191,126,639		188,333,197	
Basic earnings per share of common stock	$ 1.58		$ 0.87		$ 1.63	
Diluted earnings per share of common stock	1.53		0.84		1.58	
Adjusted basic earnings per share of common stock	1.77		0.89		1.46	
Adjusted diluted earnings per share of common stock	1.71		0.86		1.41	

(1) For the three months ended June 30, 2018, gain on sale includes a $3 gain associated with the sale of the Company's East Chicago, Indiana site. For the three months ended June 30, 2017, loss on sale includes a $2 adjustment associated with the sale of the Company's Sulfur business in 2016. For the three months ended March 31, 2018, gain on sale includes a $42 gain associated with the sale of the Company's Linden, New Jersey site.

(2) Includes costs associated with the Company's debt transactions, as well as accounting, legal, and bankers' transaction costs incurred in connection with the Company's strategic initiatives.

(3) Includes litigation settlements, PFOA drinking water treatment accruals, acquisition-related intangible asset amortization, and other charges.

(4) Includes the removal of certain discrete income tax amounts within the Company's provision for income taxes. For the three months ended June 30, 2018, adjustments made to income taxes includes $5 in windfall tax benefits on the Company's share-based payments and $3 in tax benefits resulting from unrealized losses on foreign exchange rates related to toll charges pursuant to U.S. tax reform. For the three months ended June 30, 2017, adjustments made to income taxes includes $3 in windfall tax benefits on the Company's share-based payments. For the three months ended March 31, 2018, adjustments made to income taxes includes $5 in windfall tax benefits on the Company's share-based payments.

(5) The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred and include both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.

(6) The total provision for income taxes reconciles to the amount reported in the consolidated statements of operations for the three months ended June 30, 2018 and 2017 and for the three months ended March 31, 2018.

* Note: $ per share columns may not sum due to rounding.

GAAP Net Income Attributable to Chemours to Adjusted Pre-Tax Operating Income, Adjusted Net Income, and Adjusted EPS Reconciliations (Unaudited)

($ in millions except per share amounts)	Three Months Ended June 30,			
	2018		2017	
	$ amounts	$ per share*	$ amounts	$ per share*
Net income attributable to Chemours	$ 281	$ 1.53	$ 161	$ 0.84
Provision for income taxes	41	0.22	64	0.33
Non-operating pension and other post-retirement employee benefit income	(7)	(0.04)	(10)	(0.05)
Exchange gains, net	(2)	(0.01)	(2)	(0.01)
Restructuring and other charges	9	0.05	6	0.03
Asset-related and other charges	1	0.01	2	0.01
Loss on extinguishment of debt	38	0.21	1	0.01
(Gain) loss on sale of assets or businesses (1)	(3)	(0.02)	2	0.01
Transaction costs (2)	9	0.05	2	0.01
Legal and other charges (3)	10	0.05	10	0.05
Adjusted Pre-tax Operating Income	377	2.05	236	1.23
Provision for income taxes	(41)	(0.22)	(64)	(0.33)
Adjustments made to income taxes (4)	(8)	(0.04)	(3)	(0.02)
Provision for income taxes relating to reconciling items (5)	(14)	(0.08)	(5)	(0.03)
Adjusted Net Income	$ 314	$ 1.71	$ 164	$ 0.86
Weighted-average number of common shares outstanding - basic	177,798,484		185,069,436	
Weighted-average number of common shares outstanding - diluted	183,821,241		191,126,639	
Basic earnings per share of common stock	$ 1.58		$ 0.87	
Diluted earnings per share of common stock	1.53		0.84	
Adjusted basic earnings per share of common stock	1.77		0.89	
Adjusted diluted earnings per share of common stock	1.71		0.86	

(1) For the three months ended June 30, 2018, gain on sale includes a $3 gain associated with the sale of the Company's East Chicago, Indiana site. For the three months ended June 30, 2017, loss on sale includes a $2 adjustment associated with the sale of the Company's Sulfur business in 2016.

(2) Includes costs associated with the Company's debt transactions, as well as accounting, legal, and bankers' transaction costs incurred in connection with the Company's strategic initiatives.

(3) Includes litigation settlements, PFOA drinking water treatment accruals, acquisition-related intangible asset amortization, and other charges.

(4) Includes the removal of certain discrete income tax amounts within the Company's provision for income taxes. For the three months ended June 30, 2018, adjustments made to income taxes includes $5 in windfall tax benefits on the Company's share-based payments and $3 in tax benefits resulting from unrealized losses on foreign exchange rates related to toll charges pursuant to U.S. tax reform. For the three months ended June 30, 2017, adjustments made to income taxes includes $3 in windfall tax benefits on the Company's share-based payments.

(5) The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred and include both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.

* Note: $ per share columns may not sum due to rounding.

Return on Invested Capital (ROIC) (Unaudited)

($ in millions unless otherwise noted)	Twelve Months Ended June 30, 2018	Twelve Months Ended June 30, 2017
Adjusted EBITDA (1)	$ 1,740	$ 1,153
Less: Depreciation and amortization (1)	(273)	(287)
Adjusted EBIT	1,467	866
Total debt	3,973	4,070
Total equity	1,025	572
Less: Cash and cash equivalents	(1,217)	(1,529)
Invested capital, net	$ 3,781	$ 3,113
Average invested capital (2)	$ 3,481	$ 3,158
Return on Invested Capital	42.1%	27.4%

(1) Based on amounts for the trailing 12 months ended June 30, 2018 and 2017. Reconciliations of Adjusted EBITDA to net income (loss) attributable to Chemours are provided on a quarterly basis. See the preceding tables for the reconciliation of Adjusted EBITDA to net income attributable to Chemours for the three months ended June 30, 2018 and 2017.

(2) Average invested capital is based on a five-quarter trailing average of invested capital, net.

Chemours™

Free Cash Flows Reconciliations (Unaudited)

($ in millions unless otherwise noted)	Three Months Ended			Six Months Ended	
	June 30,		March 31,	June 30,	
	2018	2017	2018	2018	2017
Cash provided by operating activities	$ 343	$ 184	$ 196	$ 539	$ 225
Less: Purchases of property, plant, and equipment	(126)	(69)	(102)	(228)	(138)
Free Cash Flows	$ 217	$ 115	$ 94	$ 311	$ 87

Chemours™

2018 Estimated GAAP Net Income Attributable to Chemours to Adjusted Net Income, Adjusted EBITDA, and Adjusted EPS Reconciliations (Unaudited)

($ in millions except per share amounts)	(Estimated) Year Ended December 31, 2018 Low	(Estimated) Year Ended December 31, 2018 High
Net income attributable to Chemours	$ 985	$ 1,080
Other adjustments	(45)	(45)
Restructuring, asset-related, and other charges, net	35	25
Provision for income taxes relating to reconciling items (1)	5	5
Adjusted Net Income	980	1,065
Interest expense, net	220	220
Depreciation and amortization	280	280
All remaining provision for income taxes	295	285
Adjusted EBITDA	$ 1,775	$ 1,850
Weighted-average number of common shares outstanding - basic (2)	179	179
Dilutive effect of the Company's employee compensation plans (2,3)	6	6
Weighted-average number of common shares outstanding - diluted (2,3)	185	185
Basic earnings per share of common stock	$ 5.50	$ 6.03
Diluted earnings per share of common stock (3)	5.32	5.84
Adjusted basic earnings per share of common stock	5.47	5.95
Adjusted diluted earnings per share of common stock (3)	5.30	5.76

(1) The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred and include both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.

(2) The Company's estimates for the weighted-average number of common shares outstanding - basic and diluted reflect results for the year ended December 31, 2017, which are carried forward for the projection period and updated for the estimated impacts of the Company's 2018 share repurchase and other activity on a weighted-average basis.

(3) Diluted earnings per share is calculated using net income available to common shareholders divided by diluted weighted-average common shares outstanding during each period, which includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.

The Company's estimates reflect its current visibility and expectations of market factors, such as, but not limited to: currency movements, titanium dioxide prices, and end-market demand. Actual results could differ materially from the current estimates due to market factors and unknown or uncertain other factors, such as non-operating pension and other post-retirement employee benefit activity with respect to the Company's foreign pension plans, including settlements or curtailments, cost savings actions that may be taken in the future, the impact of currency movements on the Company's results, including exchange gains and losses, and the related tax effects, or the impact of new accounting pronouncements.

2018 Estimated GAAP Cash Flows Provided by Operating Activities to Free Cash Flows Reconciliations (Unaudited)

($ in millions unless otherwise noted)	(Estimated) Year Ended December 31, 2018
Cash provided by operating activities	> $1,225
Less: Purchases of property, plant, and equipment	(525) - (475)
Free Cash Flows	> $700

The Company's estimates reflect its current visibility and expectations of market factors, such as, but not limited to: currency movements, titanium dioxide prices, and end-market demand. Actual results could differ materially from the current estimates due to market factors and unknown or uncertain other factors, such as non-operating pension and other post-retirement employee benefit activity with respect to the Company's foreign pension plans, including settlements or curtailments, cost savings actions that may be taken in the future, the impact of currency movements on the Company's results, including exchange gains and losses, and the related tax effects, or the impact of new accounting pronouncements.

The Chemours Company

Chemours™